<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532593</url>
  </required_header>
  <id_info>
    <org_study_id>SH9H-2020-T185-1</org_study_id>
    <nct_id>NCT04532593</nct_id>
  </id_info>
  <brief_title>Autologous Adipose Stem Cell Assisted Skin Graft</brief_title>
  <official_title>A Randomized, Placebo Controlled, Single-blinded Clinical Trial to Evaluate the Efficiency of Autologous Adipose Stem Cell in Promoting Skin Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huaxi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin graft is a commonly used method in wound repair. The long-term outcome of skin graft is&#xD;
      unsatisfied because of the complications of contraction, pigmentation and stiffness. In our&#xD;
      preclinical researches, we found that adipose stem cell can improve the texture of grafted&#xD;
      skin and reduce contraction. In this trial, we will evaluate the efficiency and safety of&#xD;
      autologous adipose stem cells in improving skin graft outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin elasticity</measure>
    <time_frame>6 months</time_frame>
    <description>Skin elasticity analyzed by Cutometer. The R2 value is used to evaluated the skin elasticity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin elasticity</measure>
    <time_frame>3 months</time_frame>
    <description>Skin elasticity analyzed by Cutometer. The R2 value is used to evaluated the skin elasticity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin elasticity</measure>
    <time_frame>12 months</time_frame>
    <description>Skin elasticity analyzed by Cutometer. The R2 value is used to evaluated the skin elasticity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin color</measure>
    <time_frame>3 months</time_frame>
    <description>Skin color analyzed by CK Colorimeter CL400. The iTA value is used to evaluate the color of skin graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin color</measure>
    <time_frame>6 months</time_frame>
    <description>Skin color analyzed by CK Colorimeter CL400. The iTA value is used to evaluate the color of skin graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin color</measure>
    <time_frame>12 months</time_frame>
    <description>Skin color analyzed by CK Colorimeter CL400. The iTA value is used to evaluate the color of skin graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of patient</measure>
    <time_frame>3 months</time_frame>
    <description>POSAS questionnaire of patient. Five questions of pain, itch, thickness, color, stiffness, irregularity. Each question ranks 0, 1, 2. Total score is 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of patient</measure>
    <time_frame>6 months</time_frame>
    <description>POSAS questionnaire of patient. Five questions of pain, itch, thickness, color, stiffness, irregularity. Each question ranks 0, 1, 2. Total score is 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of patient</measure>
    <time_frame>12 months</time_frame>
    <description>POSAS questionnaire of patient. Five questions of pain, itch, thickness, color, stiffness, irregularity. Each question ranks 0, 1, 2. Total score is 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of investigator</measure>
    <time_frame>3 months</time_frame>
    <description>POSAS questionnaire of investigator. Six questions of vascularity, pigmentation, texture, thickness, pliability, surface area. Each question ranks 0, 1, 2. Total score is 0 to 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of investigator</measure>
    <time_frame>6 months</time_frame>
    <description>POSAS questionnaire of investigator. Six questions of vascularity, pigmentation, texture, thickness, pliability, surface area. Each question ranks 0, 1, 2. Total score is 0 to 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS questionnaire of investigator</measure>
    <time_frame>12 months</time_frame>
    <description>POSAS questionnaire of investigator. Six questions of vascularity, pigmentation, texture, thickness, pliability, surface area. Each question ranks 0, 1, 2. Total score is 0 to 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Skin Graft</condition>
  <arm_group>
    <arm_group_label>Stem cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous adipose stem cell injection</intervention_name>
    <description>Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).</description>
    <arm_group_label>Stem cell group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>saline injection</intervention_name>
    <description>saline will be injected underneath skin graft (0.05 ml/cm2).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 6-70 years old;&#xD;
&#xD;
          2. Gender: male and female;&#xD;
&#xD;
          3. Scar, surface tumor or soft tissue defect evaluated to be suitable for skin grafting;&#xD;
&#xD;
          4. With two skin grafting areas and the edges more than 4cm apart;&#xD;
&#xD;
          5. Sign informed consent, participate in the study and be able to cooperate with the&#xD;
             follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are not suitable for skin grafting;&#xD;
&#xD;
          2. There who are with local lesions in the operation area, such as infection, blood&#xD;
             supply disturbance, delayed healing history, decreased soft tissue vitality, history&#xD;
             of radiotherapy or going to receive radiotherapy, active ulcer, etc;&#xD;
&#xD;
          3. With severe medical diseases (such as diabetes, hepatitis, coronary heart disease,&#xD;
             arteriosclerosis, glomerulonephritis, autoimmune diseases, etc.) were complicated;&#xD;
&#xD;
          4. Those who are receiving anticoagulant therapy and cannot suspend treatment;&#xD;
&#xD;
          5. Those who are with abnormal blood routine test, abnormal coagulation function,&#xD;
             abnormal cardiac function, abnormal liver function or renal function evaluated by&#xD;
             researchers according to the laboratory examination and other clinical signs and&#xD;
             symptoms,&#xD;
&#xD;
          6. Those who can't tolerate the operation risk according to the surgeon's evaluation;&#xD;
&#xD;
          7. Pregnant and lactating women;&#xD;
&#xD;
          8. Those who have mental illness, have no insight, can not express and cooperate with&#xD;
             each other;&#xD;
&#xD;
          9. Participant in other clinical trials within 30 days before the screen visit of this&#xD;
             trial;&#xD;
&#xD;
         10. Those who have not signed the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing-Feng Li</last_name>
    <phone>+862123271699</phone>
    <email>shuangbaizhou@yahoo.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</investigator_affiliation>
    <investigator_full_name>Qing-FengLi Li,MD</investigator_full_name>
    <investigator_title>Director, Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

